PortfoliosLab logoPortfoliosLab logo
Erasca, Inc. (ERAS)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US29479A1088
IPO Date
Jul 16, 2021

Highlights

Market Cap
$4.59B
Enterprise Value
$4.57B
EPS (TTM)
-$0.44
EBITDA (TTM)
-$140.91M
Year Range
$1.01 - $16.41
Target Price
$11.60
ROA (TTM)
-31.44%
ROE (TTM)
-38.30%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Erasca, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Erasca, Inc. (ERAS) has returned 334.95% so far this year and 1,081.02% over the past 12 months.


Erasca, Inc.

1D
8.30%
1M
18.45%
YTD
334.95%
6M
642.20%
1Y
1,081.02%
3Y*
75.17%
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jul 16, 2021, ERAS's average daily return is +0.12%, while the average monthly return is +3.14%. At this rate, your investment would double in approximately 1.9 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jan 2026 with a return of +182.5%, while the worst month was Dec 2022 at -42.9%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ERAS closed higher 48% of trading days. The best single day was Jan 7, 2026 with a return of +42.4%, while the worst single day was Dec 9, 2022 at -22.3%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026182.53%29.97%18.45%334.95%
2025-24.70%-27.51%0.00%6.57%-4.11%-9.29%11.42%10.95%38.85%11.01%30.99%17.35%48.21%
2024-21.60%42.51%-13.45%-2.43%25.37%-6.35%33.47%-8.25%-5.54%-5.13%10.42%-12.24%17.84%
2023-7.19%-10.00%-16.39%-8.31%-1.81%1.85%-4.35%-1.89%-23.94%17.26%-26.41%25.29%-50.58%
2022-23.94%4.64%-30.65%-15.35%-25.55%2.77%35.37%19.63%-13.53%4.74%-7.59%-42.91%-72.34%
202120.48%13.86%-11.25%-6.79%-28.36%9.95%-10.61%

Benchmark Metrics

Erasca, Inc. has an annualized alpha of 17.22%, beta of 1.35, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 19, 2021.

  • This stock participated in 146.41% of S&P 500 Index downside but only 111.16% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
17.22%
Beta
1.35
0.08
Upside Capture
111.16%
Downside Capture
146.41%

Return for Risk

Risk / Return Rank

ERAS ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


ERAS Risk / Return Rank: 9999
Overall Rank
ERAS Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
ERAS Sortino Ratio Rank: 9999
Sortino Ratio Rank
ERAS Omega Ratio Rank: 9898
Omega Ratio Rank
ERAS Calmar Ratio Rank: 100100
Calmar Ratio Rank
ERAS Martin Ratio Rank: 100100
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Erasca, Inc. (ERAS) and compare them to a chosen benchmark (S&P 500 Index).


ERASBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

10.99

0.90

+10.09

Sortino ratio

Return per unit of downside risk

6.16

1.39

+4.77

Omega ratio

Gain probability vs. loss probability

1.75

1.21

+0.54

Calmar ratio

Return relative to maximum drawdown

30.48

1.40

+29.08

Martin ratio

Return relative to average drawdown

99.78

6.61

+93.17

Explore ERAS risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Erasca, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Erasca, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Erasca, Inc. was 95.65%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Erasca, Inc. drawdown is 33.53%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.65%Sep 3, 2021902Apr 8, 2025
-8.89%Aug 10, 20217Aug 18, 20215Aug 25, 202112
-8.19%Aug 2, 20211Aug 2, 20215Aug 9, 20216
-5.75%Jul 23, 20212Jul 26, 20212Jul 28, 20214
-4.39%Sep 1, 20211Sep 1, 20211Sep 2, 20212

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Erasca, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Erasca, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ERAS in comparison with other companies in the Biotechnology industry. Currently, ERAS has a P/B value of 14.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items